The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Cytori Therapeutics Inc

Nasdaq: CYTX
Last

(U.S.) $2.02

Today's change+0.02 +1.00%
Updated June 24 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Cytori Therapeutics Inc

Nasdaq: CYTX
Last

(U.S.) $2.02

Today's change+0.02 +1.00%
Updated June 24 4:00 PM -4GMT. Delayed by at least 15 minutes.

Cytori Therapeutics Inc up (U.S.)$0.02

Cytori Therapeutics Inc closed up Friday by (U.S.)$0.02 or 1.00% to (U.S.)$2.02. Over the last five days, shares have lost 1.94% and are down 27.21% for the last year to date. This security has underperformed the S&P 500 by 75.20% during the last year.

Key company metrics

  • Open(U.S.) $1.95
  • Previous close(U.S.) $2.00
  • High(U.S.) $2.03
  • Low(U.S.) $1.91
  • Bid / Ask(U.S.) $0.00 / (U.S.) $2.14
  • YTD % change-27.21%
  • Volume182,386
  • Average volume (10-day)218,648
  • Average volume (1-month)261,044
  • Average volume (3-month)176,523
  • 52-week range(U.S.) $1.91 to (U.S.) $9.65
  • Beta2.58
  • Trailing P/E11.37×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.18
Updated June 24 4:00 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-17.37%

Cytori Therapeutics Inc has a net profit margin of -17.37%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX1.69%Sector:HealthcareIndustry:Medical Equipment, Supplies & Distribution
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue3323
Total other revenue--------
Total revenue3323
Gross profit2322
Total cost of revenue1111
Total operating expense850-2
Selling / general / administrative3333
Research & development4546
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--000
Other operating expenses, total--------
Operating income-5-226
Interest income (expense), net non-operating-1-1-1-1
Gain (loss) on sale of assets--000
Other--------
Income before tax-5-324
Income after tax-5-324
Income tax, total--------
Net income-5-324
Total adjustments to net income0000
Net income before extra. items-5-324
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-5-324
Inc. avail. to common incl. extra. items-5-324
Diluted net income-5-324
Dilution adjustment--------
Diluted weighted average shares13111110
Diluted EPS excluding extraordinary itemsvalue per share-0.41-0.250.140.45
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.41-0.250.150.48